Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OraVescent Fentanyl Citrate for Breakthrough Cancer Pain
NCT00105287Phase 3Completed
- Sponsor
- Cephalon, Inc.
- Start
- Jan 2005
- Primary completion
- Sep 2006
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fentanyl in breakthrough pain, sponsored by Cephalon, Inc. Primary endpoint: Safety and Tolerability. Started Jan 2005; status: completed.
02
Drugs
fentanyl
03
Conditions
breakthrough pain
Beyond the preview
Go deeper on NCT00105287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00105287.